RWPA
ABUS icon

Richard W. Paul & Associates’s Arbutus Biopharma ABUS Stock Holding History

Richard W. Paul & Associates’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-379
Closed -$872 – 513
2023
Q2 		$872 Buy
+379
New +$986 ﹤0.01% 486

Other funds holding ABUS

WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Richard W. Paul & Associates's ABUS Position: Q3 2023 in Review

Richard W. Paul & Associates sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 379 shares — an estimated $872 sold.

Richard W. Paul & Associates first reported a position in ABUS in Q2 2023 and held it in 1 quarter. The position peaked at $872 in Q2 2023. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.

  • Richard W. Paul & Associates reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
  • Richard W. Paul & Associates sold 379 Arbutus Biopharma shares in Q3 2023, an estimated $872.
  • Richard W. Paul & Associates first reported a position in Arbutus Biopharma in Q2 2023 and held it in 1 quarter.
  • Richard W. Paul & Associates's Arbutus Biopharma position peaked at $872 in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.

Based on Richard W. Paul & Associates's 13F filing for Q3 2023, filed 12 Oct 2023.